Details of the Drug Combination

General Information of Drug Combination (ID: DC5BHYM)

Drug Combination Name

Ombrabulin Ispinesib

Indication

Disease Entry	Status	REF
Ewing sarcoma	Investigative	[1]

Component Drugs

Ombrabulin DM25HY3

Ispinesib DMP2BWX

Small molecular drug

2D MOL

3D MOL

High-throughput Screening Result

Testing Cell Line: TC-71

Zero Interaction Potency (ZIP) Score: 35.229

Bliss Independence Score: 37.504

Loewe Additivity Score: 2.294

LHighest Single Agent (HSA) Score: 19.396

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of Ombrabulin

Disease Entry	ICD 11	Status	REF
Sarcoma	2A60-2C35	Phase 3	[2]

Indication(s) of Ispinesib

Disease Entry	ICD 11	Status	REF
Head and neck cancer	2D42	Phase 2	[3]
Ovarian cancer	2C73	Phase 2	[3]
Renal cell carcinoma	2C90	Phase 2	[3]
Solid tumour/cancer	2A00-2F9Z	Phase 2	[3]

Ispinesib Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Kinesin-like protein KIF11 (KIF11)	TTTRP0H	KIF11_HUMAN	Inhibitor	[4]
------------------------------------------------------------------------------------

References

1	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2	ClinicalTrials.gov (NCT00699517) A Study of AVE8062 in Advanced-stage Soft Tissue Sarcoma After Failure of Anthracycline and Ifosfamide Chemotherapies. U.S. National Institutes of Health.
3	ClinicalTrials.gov (NCT00095628) SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer. U.S. National Institutes of Health.
4	Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program. Pediatr Blood Cancer. 2009 Dec 15;53(7):1255-63.